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Abstract 
We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma 
(HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 
patients (78%) were considered at low risk, 15 (18%) at intermediate and 3 (4%) at high risk. The most relevant toxicity was 
haematological: grade 3–4 neutropenia occurred in 32% of patients, grade 3–4 anaemia in 26% of patients. Severe infections and febrile 
neutropenia were observed in 8% of patients. With a median follow-up of 35 months (range 12–55), the three-year freedom from 
treatment failure (FFTF) and overall survival (OS) were 75% (95% CI 65%–86%) and 94% (95% CI 87%–99%), respectively. The 
intensified ChlVPP/ABVVP regimen in advanced HL is effective, does not seem to differ from standard regimens in terms of FFTF and 
OS and showed a favourable toxicity profile. 
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Introduction 
Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) 
chemotherapy (CT), in combination with radiotherapy (RT) 
when necessary, is considered the treatment of choice in 
advanced HL [1–4]. However, about one third of patients with 
complete remission (CR) will subsequently relapse [5,6]. In 
recent years, intensified CT schedules have been investigated 
and there are indications for an improvement in treatment 
results [7–10]. Nonetheless, long-term toxicities should be 
considered. 
In 2003, Diehl et al [7] reported their experience with increased-
dose BEACOPP, showing a possible benefit in terms of overall 
response rate (ORR), event-free survival (EFS) and overall 
survival (OS). More recently, Federico et al [10] published a 
randomised study comparing ABVD versus BEACOPP versus 
COPPEBVCAD-CEC: a better failure-free survival (FFS) and 
progression-free survival (PFS) with the BEACOPP regimen 
was found but without any advantage in OS and a high 
incidence of grade 3–4 toxicity. 
In 2004, we reported our experience with the hybrid 
combination regimen ChlVPP/ABVVP  in advanced HL [4]: 
cycles were repeated every 4 weeks, for a maximum of eight 
administrations. Clinical results demonstrated a relevant clinical 
activity in terms of ORR (96%), 5-year EFS (71%) and OS 
(79%). Considering that grade 3–4 neutropenia precluded the 
correct delivery of CT in 67% of patients, we decided to intensify 
the schedule introducing pegylated filgrastim (pegfilgrastim). 
From February 2004 to August 2007, 82 consecutive patients 
were included, with the aim to investigate feasibility, toxicity and 
efficacy of an intensified ChlVPP/ABVVP regimen. 
 
Materials and methods 
Eligibility 
All patients had histologically confirmed and newly diagnosed 
HL. Eligible patients had stage IIA with at least one of the 
following risk factors: bulky disease (defined as mediastinal 
mass ≥ 1/3 maximum transverse thorax diameter or any lesion ≥ 
5 cm), extra-nodal involvement, erythrocyte sedimentation rate 
(ESR) ≥ 50, ≥ 3 lymph node regions involved or stage IIB , III 
and IV, with adequate renal and liver functions (serum 
creatinine level <2.5 mg/dl, total bilirubin level <1.5 mg/dl, 
AST/ALT level <2.5 times upper limit of normal). At time of 
treatment, absolute neutrophils count (ANC) should have been 
≥1.5 x 109/l, platelets (PLT) ≥ 150 x 109/l and haemoglobin (HB) 
≥ 9 g/dl. 
Patients were excluded if they had received prior CT or RT, in 
case of any other malignancy or history of prior malignancy 
(except non-melanoma skin tumours or in situ cervical 
carcinoma), uncontrolled chronic disease, HIV infection, 
psychiatric illness or pregnancy. 
The study was approved by the institutional review board, and 
written informed consent was obtained from all patients. 
 
Study design 
Patients underwent full staging, including a full patient history 
and physical examination, computed tomography (CT) scans of 
the chest, abdomen and pelvis, 18F-fluorodeoxyglucose PET 
(18FDG-PET) scanning, complete blood count (CBC), ESR, a 
biochemical profile and a bone marrow trephine biopsy.  
Treatment schedule was the following: day 1: vinblastine 6 
mg/m2 intravenously; day 1 to 7: chlorambucil 6 mg/m2/d orally, 
procarbazine 80 mg/m2/d orally, prednisone 50 mg/d orally; day 
8: doxorubicin 30 mg/m2, bleomicin 7.5 mg/ m2, vincristine 1 mg, 
intravenously; day 8 to 10:  etoposide 100 mg/ m2/d 
intravenously; day 11: Pegfilgrastim was administered at the 
dose of 6 mg subcutaneous on day 11. Cycles were repeated 
every 21 days if ANC ≥ 1.0 x 109/l and PLT ≥ 100 x 109/l. On 
day 1 of each cycle, each patient had a physical examination, a 
CBC and blood biochemistry evaluation; on day 8 and 15 only a 
CBC. Antibiotic profilaxis was not given routinely. Consolidation 
RT was delivered to the site of bulky disease in patients with a 
CR.  
As the period between pegfilgrastim administration and the 
subsequent CT cycle was <14 days , to establish the optimal 
interval, an evaluation of pegfilgrastim serum concentration was 
performed for the first group of 11 patients [11]. On the first day 
of each cycle, the pegfilgrastim serum concentration was 
evaluated using Quantikine® (human G-CSF Immunoassay), an 
enzyme-linked immunosorbent assay (ELISA test) specific for 
filgrastim. A standard curve was prepared with an upper 
concentration  of pegfilgrastim of 4 ng/ml  and a lower 
concentration of 0.062 ng/ml (Figure 1). Pegfilgrastim 
concentration was reported on x-axis and optical density on y-
axis. Sample concentrations were calculated by measuring the
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Figure 1:  Pegfilgrastin serum concentration in 34 samples evaluated on day 1 of the cycle.
optical density of the serum and extrapolating from the standard 
curve, using PC software connected to the spectrophotometer. 
Primary end points were the safety profile of the schedule in 
terms of toxicity, treatment intervals between cycles, evaluation 
of relative dose-intensity (RDI)—defined as the rapport between 
the administered dose/m2/week and the expected 
dose/m2/week. Secondary end points were FFTF and OS. 
 
Toxicity assessment 
Adverse events were assessed according to the Common 
Toxicities Criteria of the National Cancer Institute (NCI, version 
3.0) [12]. 
 
Response assessment 
Response evaluation was performed after three and six cycles 
of CT by a physical examination, CT scan of the neck, chest, 
abdomen and pelvis and an 18FDG-PET. A bone marrow biopsy 
was performed at the end of the CT program if positive for 
disease localization at baseline.  
During follow-up, clinical evaluation by physical examination 
and biochemistry was performed every three months for up to 
two years, than every six months for up to five years, and 
thereafter annually until disease progression or death. 
Radiological evaluation was performed by CT scan every six 
months for up to five years, annually thereafter for up to 10 
years. 
 Statistics 
The FFTF was calculated from the date of the first cycle to the 
date of disease progression after CR, or to the date of last 
follow-up in the case of prolonged CR. If a patient failed to 
achieve a CR, FFTF was set to zero. OS was defined as the 
time interval from the date of first cycle to the date of death or to 
the date of last follow-up if death did not occur. Survival curves 
were plotted using the Kaplan–Meier method. The log-rank test 
was used to assess survival differences between groups. The 
Kruskal–Wallis test was used to compare RDI medians. All 
analyses were carried out with the SAS software (SAS Institute, 
Cary, NC). All tests were two sided. 
 
Results 
Patient characteristics 
From February 2004 to August 2007, 82 consecutive patients 
were included in the analysis. Their characteristics are listed in 
Table 1. Median age was 34 years (range 15–68 years), 42 out 
of 82 were male. Histology included 77 classical and 5 
lymphocyte predominant HL (94% and 6%, respectively). 
According to the Hasenclever index [13], 64 out of 82 patients 
(78%) were considered at low risk, 15 (18%) at intermediate 
and 3 (4%) at high risk. 
All patients received six cycles of CT. Involved field RT was 
performed in 26 patients, with bulky disease at diagnosis and 
with CR, with a median dose of 35.5 Gy  (range: 25–37 Gy).  
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Table 1: Patient characteristics and disease status. 
Toxicity 
Haematological and non-haematological toxicities are reported 
in Table 2.  
76 out of 82 patients were evaluated for toxicity: grade 3–4 
neutropenia occurred in 24 out of 76 patients (32%), grade 3–4 
anaemia in 20 patients (26%). Transfusional support was 
required in 23 patients with a median of 2 (range 2–8) red cell 
units per patient. After the first 14 patients, darbopoietin (500 
mcg sc q 3 weeks) was introduced when the haemoglobin level 
fell to <10 g/dl, reducing the rate of transfused patients from 
57% to 24%. Febrile neutropenia and grade 3–4 infections were 
observed in six patients (8%). 
Two patients experienced asymptomatic pulmonary embolism 
after the third and fourth cycle, respectively, while one patient 
developed a cavernous sinus thrombosis after the second cycle. 
All three had received darbopoietin while in two of them, oral 
contraceptives given to preserve fertility were probably 
contributory.  
10 patients (12%) delayed treatment (nine patients one cycle, 
one patient two cycles) with a median delay time of one week 
(range one—six weeks). Delays were due to symptomatic 
neurotoxicity (one case), infectious status (seven cases; 
varicella zoster infection, flu syndrome, pneumonia and febrile 
neutropenia), thrombocytopenia (one case), gastrointestinal 
disorder (one case), cavernous sinus thrombosis (one case).   
A dose reduction of at least 20% of one drug occurred in 31 
patients: 13 patients reduced the dose for 1 drug, 12 patients for 
2 drugs and 6 patients for > 2 drugs of the schedule. Dose 
reduction was performed starting from the second cycle in eight 
patients, from the third cycle in eight patients, from the fourth 
and fifth cycle in the remaining 15 patients. The planned dose of  
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Table 2: Haematological and non-haematological  toxicity. 
doxorubicin and etoposide was reduced in three and nine 
patients, respectively; three patients reduced both, due to 
previous haematological or gastrointestinal toxicity. Vinca 
alkaloids dose reduction was mainly due to neurological toxicity. 
The RDI for each drug is reported in Table 3. The median RDI 
for all drugs was 96.95%. When these data were compared with 
those obtained from the previous experience with standard 
ChlVPP/ABVVP [4], the RDI resulted improved mainly for 
myelotoxic drugs, such as doxorubicin and etoposide.  
Pegfilgrastim 
Pegfilgrastim serum concentration was evaluated in 34 samples 
(11 patients). The median level of pegfilgrastim serum 
concentration at day 11 was 0.27 ng/ml (range 0.07–0.59 
ng/ml), well below the lowest filgrastim serum level 
concentration that can stimulate granulopoiesis (2 ng/ml), 
according to the biomathematical model that describes the 
concentration–effect relationship by an E-function [11] (Figure 
1). 
Outcome 
All patients were evaluable for response with an ORR of 99%. 
At the end of treatment, 73 out of 82 patients obtained a CR 
(89%), 8 patients a partial remission (PR) (10%) with 
histological confirmation of disease persistence available for 1, 
and 1 patient a progressive disease (PD) (1%).  
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Table 3: Comparison of relative dose intensity within standard and intensified ChlVPP/ABVVP. 
 
 
Figure 2a: Freedom from treatment failure (FFTF). 
Ten out of 73 CRs relapsed, with a median time to relapse of 9 
months (range 4–38). Autologous stem cell transplantation 
(ASCT) was performed in 17 out of 19 failures, achieving a 
second CR in 12 patients. The remaining five patients 
underwent allogenic stem cell transplantion (AlloSCT), obtaining 
a CR in one case. ASCT was not performed in two patients 
because of elderly age in the first and sub-optimal performance 
status and rapid disease progression in the latter.  
Five out of 82 patients died: four due to PD, one due to toxicity 
related to salvage CT. With a median follow-up of 35 months 
(range: 12–55) FFTF, and OS at 3 years were 75% (95% CI 
65%–86%) (Figure 2a), and 94% (95% CI 87%–99%) (Figure 
2b), respectively. When patient outcome was compared to risk 
profile, the low-risk group had a statistically significant 
advantage in terms of FFTF and OS compared to the 
intermediate risk group (p<0.001 and 0.002) (Figures 3a  and 
b). 
Discussion 
Our experience confirmed the safety and feasibility of the 
intensified ChlVPP/ABVVP regimen. A single injection of 
pegfilgrastim allowed optimal drug delivery, adequate dose 
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Figure 2b: Overall survival (OS). 
 
 
Figure 3a: Freedom from treatment failure (FFTF) according to risk profile.
intensity and a reduction in overall treatment duration if 
compared with our previously published four-week schedule [4].  
The most relevant toxicity was haematological with grade 3–4 
neutropenia in 32% of patients. Nonetheless, neutrophil 
recovery and the low rate of grade 3–4 infections make this 
schedule more favourable in terms of toxicity profile when 
compared to the standard ChlVPP/ABVVP or the 
standard/increased BEACOPP (Table 4). Symptomatic anaemia 
requiring transfusional support was one of the most relevant 
toxicities observed in the first 14 patients. Darbopoietin 
effectively reduced transfusional support, demonstrating the 
efficacy of this strategy [14]. However, thromboembolic events 
occurred in three patients: all had received darbopoietin, two 
patients also combined with oral contraceptives. It is well known
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Table 4: Grade 3–4 toxicity and outcome from other trials. 
 
 
Figure 3b: Overall survival according to risk profile. 
that the use of darbopoietin and hormonal contraception are 
associated with a 1.5-fold and a 2.0-fold increased risk of 
thrombosis, respectively [15,16]. The concomitant 
administration of CT, darbopoietin and oral contraceptives 
should be reserved to selected cases and probably requires 
adequate prophylaxis. 
 In our previous experience [4], a four-week schedule without 
pegfilgrastim, haematological toxicity and consequent CT 
delays occurred in 67% of patients, influencing the RDI of the 
schedule. The use of pegfilgrastim allowed a RDI > 80% for 
each of the drugs included in the regimen. When compared to 
the ChlVPP/ABVVP regimen [4], the RDI was significantly 
increased for doxorubicn (90.7% vs 96%, p <0.01) and 
etoposide (68.6% vs 98%, p:<0.01) without increasing toxicity .  
Second malignancies, MDS and secondary leukaemias 
represent the leading cause of excess mortality in Hodgkin 
disease survivors, correlated with the total CT dose and for RT 
with the total dose and fields involved [17–18]. The use of 
alkylating agents and etoposide is associated with an increased 
risk of short onset acute leukaemias, while solid tumours have 
emerged as the most significant late onset secondary 
malignancies [17–19]. The risk of solid tumours reported for 
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patients who received sub-total or total nodal irradiation 
compared with involved field RT is 1.84-fold higher [17–19]. 
Although the median follow-up is still short, patients who 
underwent our intensified ChlVPP/ABVVP regimen did not 
develop MDS, secondary leukaemias or secondary solid 
tumours.  
Clinical results in terms of FFTF (75%) and OS (94%) 
demonstrate the efficacy of the schedule. The use of 18FDG-
PET in the routine management of HL patients introduced more 
stringent criteria for response evaluation [20], thus the CR rate 
in our previous experience (95%) [4] was probably 
overestimated. 18FDG-PET scan restaging at the end of 
treatment modified the management of these patients:  18FDG-
PET positive patients underwent intensified CT with ASC 
support, while a negative 18FDG-PET identified patients who 
were probably cured by therapy. Relapse rate was different in 
the two groups (14% vs 24%), with an odds ratio of 2.0 (95% CI 
0.8%–4.9%). This may explain the improvement in terms of OS 
in this cohort of patients versus the previous one (94% vs 79%). 
Our results are slightly better than those reported for ABVD. 
When compared to standard BEACOPP [7], FFTF and OS are 
similar for patients with a low Hasenclever index, while the small 
number of patients with intermediate and high-risk index 
precludes any conclusion.    Results of intensified BEACOPP 
seems to be better in terms of FFTF, also at 10 years, but not of 
OS [21].  The toxicity profile and late events make this schedule 
not always  suitable for older patients or patients with co-
morbidities.  
The ASCT is an effective salvage programme [22], and an 
intensified ChlVPP/ABVVP regimen does not preclude stem cell 
mobilization since all patients taking part in the procedure 
successfully collected peripheral blood stem cells.   
In conclusion, intensified ChlVPP/ABVVP demonstrated a 
favourable profile in terms of acute and long-term toxicity, and 
seems to be–-in terms of FFTF and OS—as effective as other 
standard regimens. Patients relapsing after intensified 
ChlVPP/ABVVP regimen can be cured with the ASCT. 
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